

Active Trials

Below are just some of the current Oncology trials that are actively recruiting within the Lancashire CRF.

Trial Name	Disease Area	Principal Investigator	Study Details
BNT113	Head & Neck Cancer	Dr A. Mirza	This study is investigating whether BNT113 can help your immune system respond to and fight HPV16-positive (or HPV16+) head and neck cancers. https://ahead-merit.biontech.co.uk/en/home/study.html
BNT324-01	Lung Cancer	Dr S. Lau	This study aims to investigate the combination of BNT324, a B7-H3 antibody-drug conjugate (ADC) with BNT327, a programmed death-ligand 1 (PD-L1) and vascular endothelial growth factor (VEGF) bispecific antibody, in participants with advanced/metastatic or relapsed/progressive small cell lung cancer (SCLC) and non small cell lung cancer (NSCLC). https://clinicaltrials.biontech.com/trials/BNT324-01
BNT327-06	Lung Cancer	Dr T.C. Lam	This is a Phase 2/3, multisite, randomized, open-label study in participants with first-line non-small cell lung cancer (NSCLC). This study includes two substudies (substudy A and substudy B) that will recruit participants according to histological subtypes due to differences in chemotherapy choice for standard-of-care and type of NSCLC. https://clinicaltrials.biontech.com/trials/BNT327-06
BNT327-03	Lung Cancer	Dr A. Ali	This is a Phase III, multisite, randomized, double-blinded study to investigate pumitamig (BNT327) combined with chemotherapy (etoposide/carboplatin) compared to atezolizumab combined with chemotherapy (etoposide/carboplatin) for the treatment of

			participants with previously untreated extensive-stage small-cell lung cancer (ES-SCLC). https://clinicaltrials.biontech.com/trials/BNT327-03
OVACT	Ovarian Cancer	Professor D. Yiannakis	CryptiVax™-1001, is an off-the-shelf mRNA therapeutic vaccine in development for high-grade serous ovarian cancer. It is designed to drive targeted immune responses using a set of tumor-specific antigens chosen for broad patient coverage. https://www.epitopea.com/epitopea-announces-approval-of-ovact-clinical-trial-application-for-cryptivax-1001-in-advanced-high-grade-serous-ovarian-cancer/
Mobilize	Lung Cancer Melanoma	Professor R. Board	The Mobilize Trial is a Phase 1/2 clinical trial evaluating the safety and anti-tumor activity of an investigational mRNA treatment in adults who have select advanced solid tumor cancer. https://trials.modernatx.com/study/?id=mRNA-4359-P101
Target National	Cancer	Professor D. Yiannakis	The primary aim of TARGET National is to establish a national framework to offer molecular profiling of circulating tumor DNA and/or tumour tissue (optional) to patients with advanced solid cancers referred to any of the Experimental Cancer Medicine Centres (ECMCs) across the UK, in order to help decision making for allocation to molecularly targeted experimental cancer treatments. https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/target-national/